EEF2K — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL430666	0.98	12/20
SCHEMBL429207	0.68	11/20
SCHEMBL430534	0.98	10/20
SCHEMBL431177	0.78	10/20
SCHEMBL1539842	0.59	10/20
SCHEMBL429326	0.94	9/20
SCHEMBL427616	0.67	8/20
SCHEMBL1175798	0.57	8/20
SCHEMBL1176327	0.54	8/20
SCHEMBL1176582	0.53	8/20
SCHEMBL1176427	0.52	8/20
SCHEMBL1176458	0.55	7/20
SCHEMBL1176286	0.53	7/20
SCHEMBL1176006	0.53	7/20
SCHEMBL1176569	0.49	7/20
SCHEMBL1176092	0.42	7/20
SCHEMBL426340	0.65	6/20
SCHEMBL427979	0.64	6/20
SCHEMBL427662	0.63	6/20
SCHEMBL1953365	0.62	6/20

Clinical trials — most relevant to EEF2K by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING
Protein Balance in Protein Supplemented Elderly Patients: Acute Study With Protein-tracer-techniques	nan	WITHDRAWN
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EEF2K binder may also engage these)

Protein	Name	Similarity
P70531	—	1.000	P70531 →
O08796	—	0.997	O08796 →
Q921C3	—	0.987	Q921C3 →
Q3B7T1	—	0.985	Q3B7T1 →
Q28C33	—	0.983	Q28C33 →
KAT2B	Histone acetyltransferase KAT2B	0.983	landscape →
E9PUQ8	—	0.983	E9PUQ8 →
Q8K2L8	—	0.983	Q8K2L8 →
Q8N1G2	—	0.982	Q8N1G2 →
Q8K4M9	—	0.982	Q8K4M9 →
Q80TJ7	—	0.982	Q80TJ7 →
Q5RHD1	—	0.982	Q5RHD1 →
O01991	—	0.982	O01991 →
PTPN14	Tyrosine-protein phosphatase non-receptor type 14	0.982	landscape →
PI4KB	Phosphatidylinositol 4-kinase beta	0.982	landscape →
Q812E4	—	0.982	Q812E4 →
Q69ZX6	—	0.981	Q69ZX6 →
Q6DD21	—	0.981	Q6DD21 →
F4HZK4	—	0.981	F4HZK4 →
D3Z8X7	—	0.981	D3Z8X7 →
Q6NRE7	—	0.981	Q6NRE7 →
Q6GQV7	—	0.981	Q6GQV7 →
Q6PJI9	—	0.981	Q6PJI9 →
Q08D35	—	0.981	Q08D35 →
Q02225	—	0.981	Q02225 →
Q9JHD2	—	0.981	Q9JHD2 →
O35099	—	0.981	O35099 →
Q1LUC3	—	0.981	Q1LUC3 →
E1BTG2	—	0.981	E1BTG2 →
Q9DBC3	—	0.981	Q9DBC3 →